Prostate cancer: New insight into mechanisms of castration resistance

Nature Reviews Urology

Volumn 7, Issue 11, 2010, Pages 590-

  Payton, Sarah ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; MDV 1300; MDV 3100; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; ANTIANDROGEN THERAPY; ARTICLE; BINDING COMPETITION; CANCER GROWTH; CANCER RESISTANCE; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CELL STRAIN LNCAP; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); DRUG MECHANISM; EXON; GENETIC VARIABILITY; HUMAN; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; THERAPY EFFECT;

EID: 78549272111     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2010.171     Document Type: Article

References (2)

1. ORIGINAL ARTICLES Sun, S. et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J. Clin. Invest. 120, 2715-2730 (2010)
2. Watson, P. A. et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc. Natl Acad. Sci. USA 107, 16759-16765 (2010)